Review
Copyright ©2013 Baishideng.
World J Clin Oncol. Feb 10, 2013; 4(1): 14-24
Published online Feb 10, 2013. doi: 10.5306/wjco.v4.i1.14
Table 2 Some studies that evaluate LIG4 polymorphisms role in cancer
AuthorsLIG4 SNP identificationTumor modelEthinicityResult
Jakubowska et al[84]rs1805386Ovarian and Breast CancerCaucasianThe polymorphism was not associated with BRCA1-associated ovarian and breast cancer risk (P = 0.16 and P = 0.97, respectively)
Schildkraut et al[82]rs10131Ovarian CancerCaucasianThe polymorphism was significantly associated with invasive serous ovarian cancer risk (P < 0.05)
Pearce et al[83]rs1805386Ovarian CancerMixedThe polymorphism was initially associated with ovarian cancer risk (P = 0.007) but replication results do not confirm this association
Yin et al[93]rs1805388Non-small cell Lung CancerMixedThe polymorphism was significantly associated with the risk of severe radiation pneumonitis in non-small cell lung cancer patients who received radio(chemo)therapy (P < 0.05)
Tseng et al[94]rs1805388Non-small cell Lung CancerAsianThe polymorphism was significantly associated with lung cancer risk (P = 0.038) especially in smoking patients (P = 0.015), and with high fractional allelic loss (P = 0.016)
de las Peñas et al[89]rs1805386Non-small cell Lung CancerCaucasianThe polymorphism was not associated with survival in cisplatin/gemcitabine-treated non-small cell lung cancer patients (P = 0.31)
Sakiyama et al[95]rs2232641Lung CancerJapaneseThe polymorphism was significantly associated with a diminish risk to develop lung cancer (P = 0.03)
Sobczuk et al[96]rs2232641Breast CancerCaucasianThe polymorphism was not associated with breast cancer risk (P > 0.05)
Han et al[97]rs1805386Breast CancerMostly CaucasianNo statistically differences in breast cancer risk according LIG4 C299T or T1977C. The polymorphism T1977C was significantly associated with breast cancer risk if the patients had a first degree family history of breast cancer (P = 0.01)
rs4987182
Goode et al[98]rs1805386Breast CancerCaucasianThe polymorphism was significantly associated with the breast cancer survival (P = 0.002)
Kuschel et al[99]rs1805386Breast CancerCaucasianThe polymorphism was significantly associated with a decrease in breast cancer risk (P = 0.04)
Liu et al[100]rs3093739GliomaAsianThe polymorphism was significantly associated with glioma risk (P = 0.009)
Liu et al[101]rs7325927GlioblastomaCaucasianThe polymorphism was significantly associated with glioblastoma survival (P = 0.008)